Divis Laboratories Ltd share Price

Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues.

• In CS, the company maintains strong relationship with global big pharma players while in generics it enjoys significant market share in products like Naproxen, Dextromethorphan and Gabapentin among others
• Divi’s is fully backward integrated in products with high market share. The management intends to follow suit in other products

Beat estimates on back of strong order-book of custom synthesis.

• Sales were up 46.5% YoY to ₹ 2493.2 crore
• EBITDA was at ₹ 1097.2 crore, up 58.7% YoY with margins at 44%
• Consequent PAT was at ₹ 902.2 crore (up 91.7% YoY)

Pharmaceuticals company Divi's Laboratories announced Q1FY24 results:

• Total income of Rs 1,859 crore for Q1FY24 on a consolidated basis as against an income of Rs 2,343 crore for Q1FY23.
• Profit before Tax (PBT) for Q1FY24 amounted to Rs 492 crore as against a PBT of Rs 852 crore for Q1FY23 and a PBT of Rs 466 crore for Q4FY23.
• The Company earned a Profit after Tax (PAT) of Rs 356 crore for Q1FY24 as against a PAT of Rs 702 crore for Q1FY23. PAT for Q4FY23 was Rs 321 crore.
• Forex gain for Q1FY24 amounted to Rs 3 crore as against a gain of Rs 56 crore during Q1FY23.

Result PDF